Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rationale for evaluating North America's first medically supervised safer-injecting facility.

Evan Wood1, Thomas Kerr, Julio S Montaner

  • 1British Columbia Centre for Exellence in HIV/AIDS, St Paul's Hospital, Vancouver, Canada. ewood@cfenet.ubc.ca

The Lancet. Infectious Diseases
|May 4, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential value streams of an integrated Canadian serosurveillance network.

Canadian journal of public health = Revue canadienne de sante publique·2025
Same author

Response to letter commenting on: Do the differing vaping and smoking trends in Australia and New Zealand reflect different regulatory policies?

Addiction (Abingdon, England)·2025
Same author

Do the differing vaping and smoking trends in Australia and New Zealand reflect different regulatory policies?

Addiction (Abingdon, England)·2025
Same author

Response to commentaries on proposed regulation of nicotine vaping.

Drug and alcohol review·2023
Same author

How should nicotine vaping be regulated in Australia?

Drug and alcohol review·2023
Same author

A critique of the Australian National Health and Medical Research Council CEO statement on electronic cigarettes.

Addiction (Abingdon, England)·2023

Vancouver’s supervised safer-injecting facility (SIF) pilot aimed to reduce infectious diseases and overdose epidemics among illicit injection drug users (IDUs). The study outlines the evidence and rationale supporting this public health strategy.

Area of Science:

  • Public Health
  • Epidemiology
  • Addiction Medicine

Background:

  • Illicit injection drug users (IDUs) face significant risks, including HIV, hepatitis C virus (HCV), and bacterial infections like endocarditis.
  • Global cities grapple with ongoing infectious disease and overdose epidemics within the IDU population.
  • Conventional drug-control efforts and public health policies have limitations in addressing these critical issues.

Purpose of the Study:

  • To outline the evidence and rationale for evaluating medically supervised safer-injecting facilities (SIFs) as a public health strategy.
  • To address misunderstandings surrounding the implementation and evaluation of SIFs.
  • To support the public health initiative of Vancouver's pilot SIF.

Main Methods:

  • This article presents a review of existing evidence and the rationale behind the Vancouver SIF initiative.

Related Experiment Videos

  • It analyzes the limitations of current drug-control strategies.
  • It identifies gaps in public health policies for managing infectious diseases and overdoses among IDUs.

    • Main Results:

    • The rationale for SIFs is based on the inadequacies of traditional drug control methods.
    • SIFs address critical gaps in public health policy concerning infectious disease transmission and overdose prevention.
    • The Vancouver SIF serves as a pilot case study for this public health approach.

    Conclusions:

    • Medically supervised safer-injecting facilities offer a necessary public health intervention for IDUs.
    • SIFs are crucial for mitigating infectious disease spread and overdose incidence.
    • The Vancouver initiative demonstrates a viable strategy to address complex public health challenges faced by IDUs.